Methods for investigation of the relationship between drug- susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS Clinical Trials Group 333

Journal of Infectious Diseases

Volumn 182, Issue 1, 2000, Pages 59-67

  Sevin, Anne D ^a   DeGruttola, Victor ^a   Nijhuis, Monique ^b   Schapiro, Jonathan M ^c   Foulkes, Andrea S ^a   Para, Michael F ^d   Boucher, Charles A B ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; SAQUINAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AMINO ACID SEQUENCE; ARTICLE; CLINICAL TRIAL; CLUSTER ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; DRUG EFFECT; DRUG FORMULATION; DRUG SENSITIVITY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS CELL INTERACTION; VIRUS MUTATION; VIRUS RESISTANCE;

ADULT; AGED; CLUSTER ANALYSIS; DATA INTERPRETATION, STATISTICAL; DRUG RESISTANCE, MICROBIAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; MIDDLE AGED; PHENOTYPE; SAQUINAVIR;

EID: 0033914844     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315673     Document Type: Article

References (31)

1. 1. Durant J, Clevenbergh P, Halfon P, et al. Genotyping: the Viradapt study. Lancet 1999; 353:2195-9.
2. 2. Mayer DL. Drug-Resistant HIV-1: The virus strikes back [editorial]. JAMA 1998; 279:2000-2.
3. 3. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees. Belmont, CA: Wadsworth, 1984.
4. 4. Zhang H, Singer B. Recursive partitioning in the health sciences. New York: Springer, 1999.
5. 5. Winters MA, Baxter JD, Mayers DL, et al. Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. The Terry Beirn Community Programs for Clinical Research on AIDS. Antivir Ther 2000; 5:57-63.
6. 6. De Gruttola V, Dix L, D'Aquila, et al. The relation between baseline HIV drug resistance and response to antiviral therapy: re-analyses of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5:43-50.
7. 7. Boom R, Sol CJA, Salimans MMM, Jansen CL, Wertheim-van Dillen PME, Noordaavan der J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990; 28:495-503.
8. 8. Nijhuis, Boucher CAB, Schuurman R. Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction. Biotechniques 1995; 19:178-80.
9. 9. Maschera B, Furfine E, Blair ED. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J Virol 1995; 69:5431-6.
10. 10. Reed LJ, Muench H. A simple method for estimating fifty percent endpoints. Am J Hyg 1983; 493-7.
11. 11. Boucher CAB, Keulen W, van Bommel T, et al. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob Agents Chemother 1996; 40:2404-9.
12. 12. Hartigan JA. Clustering algorithms. New York: Wiley, 1975.
13. 13. Everitt BS. Cluster analysis. 3d ed. New York: Wiley, 1993.
14. 14. Fisher RA. The use of multiple measurements in taxonomic problems. Ann Eugenics 1936; 7:179-88.
15. 15. Panel on Discriminant Analysis, Classification, and Clustering. Discriminant analysis and clustering. Stat Sci 1989; 4:34-69.
16. 16. Therneau TM, Atkinson EJ. An introduction to recursive partitioning using the RPART routines. Rochester, MN: Mayo Clinic, 1997.
17. 17. Venables W, Ripley B. Modern applied statistics with S-PLUS. New York: Springer, 1997.
18. 18. Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996; 70:8270-6.
19. 19. Craig C, Race E, Sheldon J, et al. HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy. AIDS 1998; 12: 1611-8.
20. 20. Jacobsen H, Hanggi M, Ott M, et al. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics and frequencies. J Infect Dis 1996; 173:1379-87.
21. 21. Ruiz L, Nijhuis M, Boucher C. Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1 infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:19-28.
22. 22. Shafer RW, Hsu P, Patick AK, Craig C, Brendel V. Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors. J Virol. 1999; 73: 6197-202.
23. 23. Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM, Blair E. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 1995; 39:1704-10.
24. 24. Winters MA, Schapiro JM, Lawrence J, Merigan TC. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment. J Virol 1998; 72: 5303-6.
25. 25. Zhang Y-M, Imamichi H, Imamichi T, et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its gag substrate cleavage sites. J Virol 1997; 71:6662-70.
26. 26. Larder B, Richman D, Vella S, eds. HIV resistance and implications for therapy. Atlanta: MediCom, 1998.
27. 27. Katzenstein D, Bosch R, Shafer R, Albrecht M, Winters M, Hammer S. Classification-tree analysis of resistance mutations and virus load and failure in nelfinavir-and efavirenz-based therapies [abstract 66]. In: Programme and Abstracts of the 3rd International Workshop on HIV Drug Resistance and Treatment Strategies (San Diego). London: International Medical Press, 1999:44.
28. 28. Gingeras T, Ehm MG, Shortino DD, et al. Construction and analysis of an HIV-1 genotypic/phenotypic database confirm amino acid changes that co-occur and precede resistance [abstract 56]. In: Programme and Abstracts of the 2d International Workshop on HIV Drug Resistance and Treatment Strategies (Lake Maggiore, Italy). London: International Medical Press, 1998:38.
29. 29. Patick AK, Zhang M, Hertogs K, et al. Correlation of virologial response with genotype and phenotype of plasma HIV-1 variants in patients treated with nelfinavir in the US expanded access program [abstract 57]. In: Programme and Abstracts of the 2d International Workshop on HIV Drug Resistance and Treatment Strategies (Lake Maggiore, Italy). London: International Medical Press, 1998:39.
30. 30. Larder B, de Vroey V, Dehertogh P, Kemp S, Bloor S, Hertogs K. Predicting HIV-1 phenotypic resistance from genotype using a large phenotype-genotype relational database [abstract 59]. In: Programs and abstracts of the 3rd International Workshop on HIV Drug Resistance and Treatment Strategies (San Diego). London: International Medical Press, 1999:40.
31. 31. Para M, Collier A, Coombs R, et al. ACTG 333: relationship of baseline genotype to RNA response in ACTG 333 after switching from long term saquinavir (SQVhc) to SQV soft gelatin capsule (SQVsgc) or indinavir (IDV) [abstract 511]. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1998:175.